Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025
First multi-country study validates AI model for risk stratification and chemotherapy prediction
Excerpt from the Press Release:
SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced that three abstracts will be presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12.
The studies collectively highlight the prognostic and predictive power of Artera’s MMAI model to help personalize treatment decisions, particularly in evaluating chemotherapy benefit in post-menopausal women. Leveraging data from four independent Phase III trials across Germany, Austria, and North America, these studies validate the performance of this unique AI model across more than 7,000 patients.
“These abstracts hold tremendous weight as they cover a diverse set of patients with HR+ early breast cancer, giving clinicians a lot of confidence in the validity of these results,” said Prof. Nadia Harbeck, Director of the Breast Center at LMU University Hospital in Munich, Germany. “Traditional approaches can result in patients, especially those who are post-menopausal with node-negative tumors, receiving chemotherapy with limited benefit while still facing significant toxicities. It’s exciting to witness the emergence of new technologies that allow us to deliver the optimal breast cancer care.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?